Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273531 | 0.84 | CES2 (0.56) | ALDH1A1KMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL13689273 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL14490203 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KMT2AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL9043907 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL10908866 | 0.77 | KMT2A (0.49) | ALDH1A1KMT2AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL4273163 | 0.76 | CA12 (0.47) | ALDH1A1MAPTKDM4EALOX15POLB | |
| SCHEMBL5139133 | 0.75 | HPGD (0.68) | ALDH1A1KMT2AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL10740779 | 0.75 | SLC6A2 (0.54) | ALDH1A1KMT2AMAPTHPGDSMN1; SMN2 | |
| SCHEMBL4272093 | 0.75 | CES2 (0.51) | ALDH1A1KMT2ASMN1; SMN2MEN1KDM4E | |
| SCHEMBL1333545 | 0.74 | KMT2A (0.75) | ALDH1A1KMT2AMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910269-B1 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LAB PVT LTD (IN) | 2013-09-18 | — | — | EP | claimed |
| US-20080221358-A1 | Method of Synthesizing Key Intermediates for the Production of Camptothecin Derivatives | AVRA LABORATORIES PVT. LTD. (IN) | 2008-09-11 | — | — | US | claimed |
| EP-1910269-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | Avra Laboratories PVT. Ltd. (IN) | 2008-04-16 | — | — | EP | claimed |
| WO-2007015259-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LABORATORIES PVT. LTD. (IN) | 2007-02-08 | — | — | WO | claimed |
| EP-1910269-B1 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LAB PVT LTD (IN) | 2013-09-18 | — | — | EP | disclosed |
| US-7608740-B2 | Method of synthesizing key intermediates for the production of camptothecin derivatives | Avra Laboratories Pvt. Ltd (IN) | 2009-10-27 | — | — | US | disclosed |
| US-20080221358-A1 | Method of Synthesizing Key Intermediates for the Production of Camptothecin Derivatives | AVRA LABORATORIES PVT. LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
| EP-1910269-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | Avra Laboratories PVT. Ltd. (IN) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015259-A2 | METHOD OF SYNTHESIZING KEY INTERMEDIATES FOR THE PRODUCTION OF CAMPTOTHECIN DERIVATIVES | AVRA LABORATORIES PVT. LTD. (IN) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221358-A1 | Method of Synthesizing Key Intermediates for the Production of Camptothecin Derivatives | DHPS, TOP2A, HCCS | ALDH1A1 1104/4885KMT2A 3665/4885MAPT 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.